

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTASXJ1617

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom  
IPC display formats  
NEWS 3 MAR 31 CAS REGISTRY enhanced with additional experimental  
spectra  
NEWS 4 MAR 31 CA/Caplus and CASREACT patent number format for U.S.  
applications updated  
NEWS 5 MAR 31 LPCI now available as a replacement to LDPCI  
NEWS 6 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements  
NEWS 7 APR 04 STN AnaVist, Version 1, to be discontinued  
NEWS 8 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new  
predefined hit display formats  
NEWS 9 APR 28 EMBASE Controlled Term thesaurus enhanced  
NEWS 10 APR 28 IMSRESEARCH reloaded with enhancements  
NEWS 11 MAY 30 INPAFAMDB now available on STN for patent family  
searching  
NEWS 12 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology  
sequence search option  
NEWS 13 JUN 06 EPFULL enhanced with 260,000 English abstracts  
NEWS 14 JUN 06 KOREAPAT updated with 41,000 documents  
NEWS 15 JUN 13 USPATFULL and USPAT2 updated with 11-character  
patent numbers for U.S. applications  
NEWS 16 JUN 19 CAS REGISTRY includes selected substances from  
web-based collections  
NEWS 17 JUN 25 CA/Caplus and USPAT databases updated with IPC  
reclassification data  
NEWS 18 JUN 30 AEROSPACE enhanced with more than 1 million U.S.  
patent records  
NEWS 19 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional  
options to display authors and affiliated  
organizations  
NEWS 20 JUN 30 STN on the Web enhanced with new STN AnaVist  
Assistant and BLAST plug-in  
NEWS 21 JUN 30 STN AnaVist enhanced with database content from EPFULL  
NEWS 22 JUL 28 CA/Caplus patent coverage enhanced  
NEWS 23 JUL 28 EPFULL enhanced with additional legal status  
information from the epoline Register  
NEWS 24 JUL 28 IFICDB, IFIPAT, and IFIUDB reloaded with enhancements  
NEWS 25 JUL 28 STN Viewer performance improved  
NEWS 26 AUG 01 INPADOCDB and INPAFAMDB coverage enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:21:34 ON 07 AUG 2008

=>

=> file hcaplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 12:21:48 ON 07 AUG 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Aug 2008 VOL 149 ISS 6

FILE LAST UPDATED: 6 Aug 2008 (20080806/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s methylphenidate melatonin adhd  
2313 METHYLPHENIDATE  
15197 MELATONIN  
1533 ADHD

L1 0 METHYLPHENIDATE MELATONIN ADHD  
(METHYLPHENIDATE(W)MELATONIN(W)ADHD)

=> s methylphenidate and melatonin and adhd  
2313 METHYLPHENIDATE  
15197 MELATONIN  
1533 ADHD

L2 2 METHYLPHENIDATE AND MELATONIN AND ADHD

=> d 12

L2 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2004:287781 HCAPLUS  
 DN 140:281402  
 TI Combined use of methylphenidate and melatonin for  
 treating attention-deficit hyperactive disorder  
 IN Kruisinga, Roelof Johannes Hendrik  
 PA Pooger Properties Limited, UK  
 SO PCT Int. Appl., 13 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004028532	A1	20040408	WO 2003-EP10827	20030926
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2500198	A1	20040408	CA 2003-2500198	20030926
	AU 2003270292	A1	20040419	AU 2003-270292	20030926
	EP 1545511	A1	20050629	EP 2003-750659	20030926
	EP 1545511	B1	20070509		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	AT 361747	T	20070615	AT 2003-750659	20030926
	ES 2287512	T3	20071216	ES 2003-750659	20030926
	US 20060167050	A1	20060727	US 2006-529341	20060213
PRAI	EP 2002-21810	A	20020926		
	WO 2003-EP10827	W	20030926		
RE.CNT 4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

=> d 12 2

L2 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2002:878171 HCAPLUS  
 DN 139:750  
 TI Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in Attention Deficit/Hyperactivity Disorder  
 AU Bymaster, Frank P.; Katner, Jason S.; Nelson, David L.; Hemrick-Luecke, Susan K.; Threlkeld, Penny G.; Heiligenstein, John H.; Morin, S. Michelle; Gehlert, Donald R.; Perry, Kenneth W.  
 CS Neuroscience Research Division, Lilly Research Laboratories, Indianapolis, IN, USA  
 SO Neuropsychopharmacology (2002), 27(5), 699-711  
 CODEN: NEROEW; ISSN: 0893-133X  
 PB Elsevier Science Inc.  
 DT Journal  
 LA English  
 RE.CNT 88 THERE ARE 88 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 12 2 ibib abs

L2 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:878171 HCAPLUS

DOCUMENT NUMBER: 139:750

TITLE: Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in Attention Deficit/Hyperactivity Disorder

AUTHOR(S): Bymaster, Frank P.; Katner, Jason S.; Nelson, David L.; Hemrick-Luecke, Susan K.; Threlkeld, Penny G.; Heiligenstein, John H.; Morin, S. Michelle; Gehlert, Donald R.; Perry, Kenneth W.

CORPORATE SOURCE: Neuroscience Research Division, Lilly Research Laboratories, Indianapolis, IN, USA

SOURCE: Neuropsychopharmacology (2002), 27(5), 699-711

CODEN: NEROEW; ISSN: 0893-133X

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The selective norepinephrine (NE) transporter inhibitor atomoxetine (formerly called tomozetine or LY139603) has been shown to alleviate symptoms in Attention Deficit/Hyperactivity Disorder (ADHD). We investigated the mechanism of action of atomoxetine in ADHD by evaluating the interaction of atomoxetine with monoamine transporters the effects on extracellular levels of monoamines, and the expression of the neuronal activity marker Fos in brain regions. Atomoxetine inhibited binding of radioligands to clonal cell lines transfected with human NE, serotonin (5-HT) and dopamine (DA) transporters with dissociation constants ( $K_i$ ) values of 5, 77 and 1451 nM, resp., demonstrating selectivity for NE transporters. In microdialysis studies, atomoxetine increased extracellular (EX) levels of NE in prefrontal cortex (PFC) 3-fold, but did not alter 5-HT levels. Atomoxetine also increased DAEX concns. in PFC 3-fold, but did not alter DAEX in striatum or nucleus accumbens. In contrast, the psychostimulant methylphenidate, which is used in ADHD therapy, increased NEEX and DAEX equally in PFC, but also increased DAEX in the striatum and nucleus accumbens to the same level. The expression of the neuronal activity marker Fos was increased 3.7-fold in PFC by atomoxetine administration, but was not increased in the striatum or nucleus accumbens, consistent with the regional distribution of increased DAEX. We hypothesize that the atomoxetine-induced increase of catecholamines in PFC, a region involved in attention and memory, mediates the therapeutic effects of atomoxetine in ADHD. In contrast to methylphenidate, atomoxetine did not increase DA in striatum or nucleus accumbens, suggesting it would not have motoric or drug abuse liabilities.

REFERENCE COUNT: 88 THERE ARE 88 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s melatonin and adhd  
15197 MELATONIN  
1533 ADHD

L3 7 MELATONIN AND ADHD

=> d 13 1-7 abs ibib

L3 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN

AB A review. In recent years, there has been a growing interest in sleep problems associated with attention-deficit/hyperactivity disorder (ADHD). The etiol. of these sleep problems is multifactorial. In

this paper, we review the current literature on the treatment of the most common disorders or factors underlying sleep problems associated with ADHD. In particular, we focus on the management of sleep problems associated with ADHD medications, restless legs syndrome, excessive nocturnal motricity in sleep, sleep disordered breathing, sleep-onset insomnia and psychiatric comorbidities associated with ADHD. Given the paucity of randomized, controlled, double-blinded, placebo-controlled studies, it is hoped that this review will encourage further methodol. sound studies in order to be able to develop treatment guidelines.

ACCESSION NUMBER: 2007:1382103 HCAPLUS  
DOCUMENT NUMBER: 148:486114  
TITLE: Sleep problems associated with ADHD: a review of current therapeutic options and recommendations for the future  
AUTHOR(S): Lecendreux, Michel; Cortese, Samuele  
CORPORATE SOURCE: Centre Pediatrique des Pathologies du Sommeil, Hopital Robert Debre, Paris, 75019, Fr.  
SOURCE: Expert Review of Neurotherapeutics (2007), 7(12), 1799-1806  
CODEN: ERNXAR; ISSN: 1473-7175  
PUBLISHER: Future Drugs Ltd.  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English  
REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2008 ACS ON STN

AB The present invention relates to a method for determining likelihood of an individual of developing a psychiatric disorder by screening for polymorphisms in ASMT and AANAT genes. Polymorphisms in ASMT gene encoding acetyl serotonin methyltransferase and AANAT gene encoding arylalkylamine acetyltransferase decrease melatonin synthesis and are associated with psychiatric disorders. Psychiatric disorder may include autism spectrum disorders (ASD), attention deficits and hyperactivity disorder (ADHD) and anorexia.

ACCESSION NUMBER: 2007:426710 HCAPLUS  
DOCUMENT NUMBER: 146:439790  
TITLE: Polymorphisms in ASMT and AANAT genes decreasing melatonin synthesis and conferring susceptibility to psychiatric disorders and methods for diagnosis and treatment  
INVENTOR(S): Launay, Jean-Marie; Melke, Jonas; Bourgeron, Thomas; Leboyer, Marion; Goubran-Botros, Hany; Gillberg, Christopher  
PATENT ASSIGNEE(S): Institut Pasteur, Fr.  
SOURCE: Can. Pat. Appl., 49pp.  
CODEN: CPXXEB  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2523399	A1	20070414	CA 2005-2523399	20051014
CA 2564064	A1	20070414	CA 2006-2564064	20061013
CA 2625639	A1	20070510	CA 2006-2625639	20061013
WO 2007052166	A2	20070510	WO 2006-1B3935	20061013
WO 2007052166	A3	20071004		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,

KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,  
 MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,  
 RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, SG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AF, EA, EF, OA  
 EP 1948830 A2 20080730 EP 2006-842364 20061013  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR  
 PRIORITY APPLN. INFO.: CA 2005-2523399 A 20051014  
 WO 2006-IB3935 W 20061013

L3 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2008 ACS ON STN  
 AB Idiopathic chronic sleep onset insomnia (SOI) in children with  
 Attention-Deficit/Hyperactivity Disorder (ADHD) shows typical  
 characteristics of the delayed sleep phase syndrome and could, therefore,  
 be considered a circadian rhythm sleep disorder. A variable number tandem  
 repeat (VNTR) polymorphism of the clock gene PER3 is associated with the  
 delayed sleep phase syndrome and, hence, may associate with ADHD  
 -related chronic SOI as well. Here, we investigated an association between  
 ADHD-related chronic SOI and the VNTR polymorphism of PER3 in 10  
 medication naive children with rigorously diagnosed ADHD and SOI  
 (ADHD-SOI), and in 10 normal controls. Actigraphic sleep onset  
 and sleep duration and salivary dim light melatonin onset (DLMO)  
 were evaluated in ADHD-SOI. The 4-repeat allele frequency was  
 lower in ADHD-SOI (0.65) than in normal controls (0.75) ( $p =$   
 0.73) with an odds ratio of 0.62 (CI 0.16 - 2.4). In ADHD-SOI,  
 mean ( $\pm$ SD) DLMO ( $21:38 \pm 0:50$  h), sleep onset ( $22:17 \pm 0:46$  h),  
 and sleep duration ( $9:26 \pm 0:41$  h) were not significantly related to  
 the 4-repeat allele frequency. The present findings suggest no association  
 between ADHD-related idiopathic chronic sleep onset insomnia and  
 the PER3 VNTR polymorphism.

ACCESSION NUMBER: 2006:46097 HCAPLUS  
 DOCUMENT NUMBER: 145:5642  
 TITLE: No evidence to support an association of PER3 clock  
 gene polymorphism with ADHD-related  
 idiopathic chronic sleep onset insomnia  
 AUTHOR(S): van der Heijden, Kristiaan B.; Blok, Marinus J.; Spee,  
 Kim; Archer, Simon N.; Smits, Marcel G.; Curfs,  
 Leopold M.; Gunning, W. Boudewijn  
 CORPORATE SOURCE: Department of Child and Adolescent Psychiatry,  
 University of Amsterdam, Amsterdam, Neth.  
 SOURCE: Biological Rhythm Research (2005), 36(5), 381-388  
 CODEN: BRHREI; ISSN: 0929-1016  
 PUBLISHER: Taylor & Francis Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2008 ACS ON STN  
 AB The invention discloses a method for controlling feelings of pain in  
 infants or diseased or elderly persons using a complete nutrition or a  
 nutritional supplement. The method comprises administering increased  
 levels of folic acid, vitamin B6 and vitamin B12 or their functional  
 equivalent  
 ACCESSION NUMBER: 2005:1224671 HCAPLUS  
 DOCUMENT NUMBER: 143:452903  
 TITLE: Nutritional composition for relieving discomfort

INVENTOR(S): Hageman, Robert Johan Joseph; Bindels, Jacob Geert  
 PATENT ASSIGNEE(S): Neth.  
 SOURCE: U.S. Pat. Appl. Publ., 10 pp., Cont.-in-part of U.S.  
 Ser. No. 889,793.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050256031	A1	20051117	US 2005-125201	20050510
EP 951842	A2	19991027	EP 1999-201359	19990429
EP 951842	A3	19991222		
EP 951842	B1	20021204		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 2000043013	A1	20000727	WO 2000-NL42	20000120
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6900180	B1	20050531	US 2001-889793	20011024
US 20080145451	A1	20080619	US 2008-33379	20080219
PRIORITY APPLN. INFO.:				
			EP 1999-200166	A 19990120
			EP 1999-201359	A 19990429
			WO 2000-NL42	W 20000120
			US 2001-889793	A2 20011024
			US 2005-125201	A3 20050510

L3 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2008 ACS on STN  
 AB The invention relates to the combined use of Me phenidate and at least one  
 of melatonin, a melatonin analog, or a  
 pharmaceutically acceptable salt thereof in the treatment of attention  
 deficit hyperactive disorder (ADHD). Methylphenidate and  
 melatonin or its analog may be used together or in combination  
 with one or more other active ingredients, and is preferably formulated as  
 a composition for controlled release.

ACCESSION NUMBER: 2004:287781 HCAPLUS  
 DOCUMENT NUMBER: 140:281402  
 TITLE: Combined use of methylphenidate and melatonin  
 for treating attention-deficit hyperactive disorder  
 Kruisinga, Roelof Johannes Hendrik  
 INVENTOR(S):  
 PATENT ASSIGNEE(S): Pooger Properties Limited, UK  
 SOURCE: PCT Int. Appl., 13 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028532	A1	20040408	WO 2003-EP10827	20030926
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,				

LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,  
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
CA 2500198 A1 20040408 CA 2003-2500198 20030926  
AU 2003270292 A1 20040419 AU 2003-270292 20030926  
EP 1545511 A1 20050629 EP 2003-750659 20030926  
EP 1545511 B1 20070509  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
AT 361747 T 20070615 AT 2003-750659 20030926  
ES 2287512 T3 20071216 ES 2003-750659 20030926  
US 20060167050 A1 20060727 US 2006-529341 20060213  
PRIORITY APPLN. INFO.: EP 2002-21810 A 20020926  
WO 2003-EP10827 W 20030926  
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2008 ACS ON STN  
AB The selective norepinephrine (NE) transporter inhibitor atomoxetine  
(formerly called tomoxetine or LY139603) has been shown to alleviate  
symptoms in Attention Deficit/Hyperactivity Disorder (ADHD). We  
investigated the mechanism of action of atomoxetine in ADHD by  
evaluating the interaction of atomoxetine with monoamine transporters the  
effects on extracellular levels of monoamines, and the expression of the  
neuronal activity marker Fos in brain regions. Atomoxetine inhibited  
binding of radioligands to clonal cell lines transfected with human NE,  
serotonin (5-HT) and dopamine (DA) transporters with dissociation consts. (K<sub>i</sub>)  
values of 5, 77 and 1451 nM, resp., demonstrating selectivity for NE  
transporters. In microdialysis studies, atomoxetine increased  
extracellular (EX) levels of NE in prefrontal cortex (PFC) 3-fold, but did  
not alter 5-HT levels. Atomoxetine also increased DAEX concns. in PFC  
3-fold, but did not alter DAEX in striatum or nucleus accumbens. In  
contrast, the psychostimulant methylphenidate, which is used in  
ADHD therapy, increased NEEX and DAEX equally in PFC, but also  
increased DAEX in the striatum and nucleus accumbens to the same level.  
The expression of the neuronal activity marker Fos was increased 3.7-fold  
in PFC by atomoxetine administration, but was not increased in the  
striatum or nucleus accumbens, consistent with the regional distribution  
of increased DAEX. We hypothesize that the atomoxetine-induced increase  
of catecholamines in PFC, a region involved in attention and memory,  
mediates the therapeutic effects of atomoxetine in ADHD. In  
contrast to methylphenidate, atomoxetine did not increase DA in striatum  
or nucleus accumbens, suggesting it would not have motoric or drug abuse  
liabilities.

ACCESSION NUMBER: 2002:878171 HCAPLUS  
DOCUMENT NUMBER: 139:750  
TITLE: Atomoxetine increases extracellular levels of  
norepinephrine and dopamine in prefrontal cortex of  
rat: a potential mechanism for efficacy in Attention  
Deficit/Hyperactivity Disorder  
AUTHOR(S): Bymaster, Frank P.; Katner, Jason S.; Nelson, David  
L.; Hemrick-Luecke, Susan K.; Threlkeld, Penny G.;  
Heiligenstein, John H.; Morin, S. Michelle; Gehlert,  
Donald R.; Perry, Kenneth W.  
CORPORATE SOURCE: Neuroscience Research Division, Lilly Research  
Laboratories, Indianapolis, IN, USA  
SOURCE: Neuropharmacology (2002), 27(5), 699-711  
CODEN: NEROEW; ISSN: 0893-133X



PUBLISHER: Elsevier Science Inc.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 REFERENCE COUNT: 88 THERE ARE 88 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2008 ACS ON STN  
 AB The present invention relates to the use of at least one of  
 melatonin, a melatonin analog, or a pharmaceutically  
 acceptable salt thereof in the treatment of attention deficit-  
 hyperactivity disorder (ADHD). Melatonin or its  
 analog may be used alone or in combination with one or more other active  
 ingredients, and is preferably formulated as a composition for controlled  
 release.

ACCESSION NUMBER: 2002:754208 HCAPLUS  
 DOCUMENT NUMBER: 137:268465  
 TITLE: Use of melatonin in the manufacture of a  
 medicament for treating attention deficit-  
 hyperactivity disorder

INVENTOR(S): Kruisinga, Roelof Johannes Hendrik  
 PATENT ASSIGNEE(S): Pooger Properties Limited, UK  
 SOURCE: PCT Int. Appl., 14 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076452	A1	20021003	WO 2002-EP3317	20020322
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1243265	A1	20020925	EP 2001-201094	20010322
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
CA 2357114	A1	20020922	CA 2001-2357114	20010906
AU 2002242734	A1	20021008	AU 2002-242734	20020322
EP 1370259	A1	20031217	EP 2002-708364	20020322
EP 1370259	B1	20070117		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004524344	T	20040812	JP 2002-574967	20020322
ES 2280510	T3	20070916	ES 2002-708364	20020322
US 20040097577	A1	20040520	US 2003-472029	20031118
PRIORITY APPLN. INFO.:			EP 2001-201094	A 20010322
			WO 2002-EP3317	W 20020322
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	106.40	106.61
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-6.40	-6.40

STN INTERNATIONAL LOGOFF AT 12:39:36 ON 07 AUG 2008